达雷妥尤单抗联合来那度胺+地塞米松方案治疗老年 难治性多发性骨髓瘤的效果及短期预后观察.

OBJECTIVE: To probe into the efficacy of daratumumab combined with lenalidomide and dexamethasone in the treatment of elderly refractory multiple myeloma and its short-term prognosis. METHODS: A total of 82 patients with multiple myeloma admitted to Huanggang Central Hospital from Jan. 2020 to Jan. 2022 were selected as research objects, those patients were divided into 41 cases in the observation group ( treated with daratumumab combined with lenalidomide + dexamethasone ) and 41 cases in the control group ( treated with lenalidomide + dexamethasone ). The efficacy, degrees of myelosuppression, grades of peripheral neuropathy, incidences of adverse drug reactions and short-term prognosis of both groups were observed. RESULTS: The strict complete remission rate of the observation group was 21. 95% (9 / 41), which was higher than 4. 88% (2 / 41) of the control group, with statistically significant difference ( P < 0. 05). After treatment, the proportion of degree Ⅱ of myelosuppression was 7. 32% (3 / 41) in the observation group, lower than 26. 83% (11 / 41) in the control group, with statistically significant difference (P< 0. 05). After treatment, the percentage of grade Ⅱ and grade Ⅰ-Ⅳ of peripheral neuropathy were respectively 4. 87% (2 / 41) and 24. 39% (10 / 41) in the observation group, lower than 26. 83% (11 / 41) and 48. 78% (20 / 41) in the control group, with statistically significant differences (P<0. 05). There was no statistically significant difference in total incidences of adverse drug reactions between two groups (P> 0. 05). The M protein content, abnormal plasma cell, β2-microglobulin and blood calcium value of the observation. [ABSTRACT FROM AUTHOR]